Kalvista Pharmaceuticals Inc (KALV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kalvista Pharmaceuticals Inc (KALV) has a cash flow conversion efficiency ratio of -1.923x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.68 Million) by net assets ($17.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see KALV market cap for the company's overall valuation and market capitalisation.
Kalvista Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Kalvista Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Kalvista Pharmaceuticals Inc stock quote for real-time trading data and today's change.
Kalvista Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kalvista Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Review Kalvista Pharmaceuticals Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adapthealth Corp
NASDAQ:AHCO
|
0.099x |
|
Africa Oil Corp
TO:AOI
|
0.039x |
|
SK Discovery Co Ltd
KO:006120
|
-0.012x |
|
Hna-Caissa Travel Group Co Ltd
SHE:000796
|
-0.094x |
|
Dashang Co Ltd
SHG:600694
|
0.006x |
|
Mako Mining Corp Common Stock
NASDAQ:MAKO
|
0.137x |
|
Thunder Tiger Corp
TW:8033
|
-0.014x |
|
Oxford Lane Capital Corp
NASDAQ:OXLC
|
0.240x |
Annual Cash Flow Conversion Efficiency for Kalvista Pharmaceuticals Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Kalvista Pharmaceuticals Inc from 2013 to 2025. Also see KALV current and non-current assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $95.39 Million | $-152.91 Million | -1.603x | -271.10% |
| 2024-04-30 | $206.58 Million | $-89.23 Million | -0.432x | +7.58% |
| 2023-04-30 | $161.03 Million | $-75.26 Million | -0.467x | -10.72% |
| 2022-04-30 | $185.09 Million | $-78.13 Million | -0.422x | -259.85% |
| 2021-04-30 | $257.19 Million | $-30.17 Million | -0.117x | +78.08% |
| 2020-04-30 | $83.75 Million | $-44.82 Million | -0.535x | -42.35% |
| 2019-04-30 | $96.74 Million | $-36.37 Million | -0.376x | -197.03% |
| 2018-04-30 | $27.25 Million | $10.56 Million | 0.387x | +151.16% |
| 2017-04-30 | $31.33 Million | $-23.72 Million | -0.757x | -23.73% |
| 2016-04-30 | $21.50 Million | $-13.16 Million | -0.612x | -418.50% |
| 2016-03-31 | $43.07 Million | $-5.08 Million | -0.118x | +72.10% |
| 2015-12-31 | $49.31 Million | $-20.86 Million | -0.423x | -393.54% |
| 2015-04-30 | $-44.18 Million | $-6.37 Million | 0.144x | -94.08% |
| 2014-12-31 | $-4.62 Million | $-11.25 Million | 2.433x | +1588.23% |
| 2014-04-30 | $-33.71 Million | $-4.86 Million | 0.144x | +122.15% |
| 2013-04-30 | $-28.29 Million | $-1.83 Million | 0.065x | -- |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more